Navigation Links
FDA Panel to Vote on New 'Morning After' Pill
Date:6/17/2010

Marketed as ellaOne in Europe, backers say it extends window of emergency contraception, but opponents see it as abortion drug

THURSDAY, June 17 (HealthDay News) -- A U.S. Food and Drug Administration advisory panel plans to vote Thursday on whether to approve a new emergency contraception pill that is effective for a longer period of time than the "morning after" pill known as Plan B.

The new drug, ulipristal acetate or UPA, is marketed under the brand name ellaOne and would be available only by prescription; it would be effective if taken up to five days after unprotected intercourse. Plan B, another emergency contraceptive, is only effective for up to three days after unprotected sex.

Although the FDA does not always follow the recommendations of its advisory panels, it typically does.

UPA, which is already marketed in 22 European countries, is made by French pharmaceutical company HRA Pharma.

The drug works by inhibiting ovulation, explained Dr. Paul Fine, medical director of Planned Parenthood of Houston & Southeast Texas & Louisiana and a professor of obstetrics, gynecology and urology at Baylor College of Medicine in Houston.

Fine was author of a study published earlier this year in The Lancet that found that UPA cut the risk of an unintended pregnancy in half as compared with levonorgestrel (also known as Plan B, which is now available over-the-counter) in women who took it within five days of unprotected sex.

The possibility of the FDA giving a green light to ellaOne has sparked intense debate as to whether the pill simply prevents pregnancy or actually induces an abortion.

"It is not an abortion pill," said Fine. "The reason for this is that if ovulation has already occurred and fertilization has occurred, then the pregnancy is going to happen. That is also true with Plan B."

"All we can hope is that the FDA advisory committee will listen to the science that's presented, and the science is very compelling that this is a very safe and very effective drug for emergency contraception," he added.

But anti-abortion advocates disagree.

According to Dr. Joe DeCook, a spokesman for the American Association of Pro-Life Obstetricians and Gynecologists (AAPLOG), at the doses recommended, ulipristal will not suppress ovulation but will, rather, "block the lining of the uterus from receiving progesterone, which makes it dysfunctional. It will not then support life."

"Life starts when the egg is fertilized. You have a complete genetic human being in a progressive growth stage just like you or me, just smaller than us and less developed," he added. "Ulipristal purposely causes the death of a complete human being, albeit very small and very early. We don't believe it is correct to purposely kill an innocent unborn child, no matter how small."

AAPLOG also has objections on safety grounds, the track record of studies conducted on the pill and, especially, the fact that there is a lack of data on the use of minors using the drug.

An FDA report issued earlier this week found UPA to be safe with no untoward side effects, reported Agence France-Presse (AFP). The FDA's review found the most common side effects to be nausea, headache, uterine pain, abdominal pain, fatigue and dizziness, AFP said.

Other more serious side effects did not seem to be due to the drug, the FDA stated.

At lower doses, UPA is being tested in late clinical trials as a treatment for uterine fibroids, according to Planned Parenthood.

More information

For more on contraception, visit the U.S. National Library of Medicine.



SOURCES: Paul Fine, M.D., medical director, Planned Parenthood of Houston & Southeast Texas & Louisiana, and professor, obstetrics, gynecology and urology, Baylor College of Medicine, Houston; Joseph DeCook, M.D., spokesman, American Association of Pro-Life Obstetricians and Gynecologists; Agence France-Presse


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. U.S. Panel Upholds Ban on Gay Men as Blood Donors
2. John Theurer Cancer Center and LLS host panel discussion with leading hematologists
3. DSPanel's New Mobile Analytics Server for Business Intelligence: Data Analysis, Monitoring and Planning When and Where You Need It
4. ANY LAB TEST NOW Launches New Infectious Disease Panels - Affordable Panels Test for H1N1, Staph, E. coli and Other Infectious Diseases
5. PSA-TEC to Present State of the Industry Panel Discussion
6. Panel recommends standardizing prescription container labeling
7. HIA-LI 22nd Annual Business Trade Show & Conference to Feature Healthcare Pavilion and Expert Panel Discussing Healthcare Economics and Politics
8. Review Panel Leaves Controversial Lyme Disease Guidelines Unchanged
9. R. Shane Jackson Selected as Panelist for Center for Health Transformation Member Meeting
10. FDA Panel Weighs New Restrictions on Tanning Beds
11. Panel: FCCs Broadband Plan Will Boost Efforts to Expand Health IT
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Panel to Vote on New 'Morning After' Pill
(Date:2/5/2016)... ... 2016 , ... In the fourth quarter of 2015, document ... La Valencia Hotel in San Diego, California to discuss changes in the industry ... outstanding franchise, walking away with the coveted David Wright Award of Excellence. ...
(Date:2/5/2016)... ... 2016 , ... Pivot Point Consulting, a leading national Healthcare ... Services for HIT Implementation Support & Staffing report with an outstanding score of ... healthcare executives, managers and clinicians representing over 4,500 hospitals and 2,500 clinics. , ...
(Date:2/5/2016)... ... 05, 2016 , ... Colorize is a web theme package created ... next using Colorize's dynamic moving camera. Colorize is perfect for personal and web related ... environment with 1 to 5 focus points per scene, stage floor scene presets that ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Calls Blacklist has ... completely new user interface design and the developer has fixed known bugs within the ... want to on their phone while not consuming any of their device’s battery power ...
(Date:2/4/2016)... Palos Verdes, CA (PRWEB) , ... February 04, ... ... present at the "It's All About YOU Re-Treat" on February 19-21, 2016, ... You Re-Treat" is at Rancho Palos Verdes, California. These 30 professional speakers, including ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... 4, 2016 Frontier Pharma: Chronic Obstructive ... Innovation Chronic Obstructive Pulmonary Disease ... inflammation of the airways and lungs. Persistent breathing ... the disease one of the leading causes of ... the world. COPD is linked to cumulative exposure ...
(Date:2/4/2016)... Feb. 4, 2016 In response to the opioid ... Deputy Commissioner for Medical Products and Tobacco, along with other ... the agency,s approach to opioid medications. The plan will focus ... patients in pain access to effective relief. ... , Re-examine the risk-benefit paradigm for opioids and ensure ...
Breaking Medicine Technology: